Clinical health publishing
Written by licensed PharmDs, reviewed by practicing physicians. No ads disguised as content. No fluff, no filler.
GLP‑1 microdosing — taking low doses of Ozempic, Wegovy, or tirzepatide — is all over social media. Here's what the evidence actually shows about whether it works for weight, metabolic health, and longevity — and the risks nobody mentions.
GLP‑1 drugs like Ozempic, Wegovy, and Zepbound cause real lean mass loss. Here's what the clinical trials actually show — and how to protect your muscle.
Eli Lilly's orforglipron just became the first GLP‑1 pill you can take any time of day, with or without food. Here's what the clinical trials show, how it stacks up against injectables, and who should be asking their doctor about it.
What actually happens when you stop taking Ozempic or Wegovy — the weight regain data, the physiology behind it, discontinuation symptoms, and what to know before you stop.
Retatrutide's Phase 2 data showed 24% weight loss — more than any approved GLP‑1 drug. It's also not FDA-approved, can't be legally compounded, and is being sold at med spas anyway. The science, the hype, and why you should wait.
Ozempic and Mounjaro dominate headlines, but most coverage misses the clinical substance. Semaglutide vs. tirzepatide on mechanism, efficacy, cardiovascular outcomes data, side effects, and who each drug is actually best for.
The FDA has ended the legal basis for compounded semaglutide and tirzepatide, and major telehealth platforms have already exited the market. The regulatory timeline, what it means for patients mid-treatment, and what your real options are right now.
The real clinical differences between compounded semaglutide and brand-name Ozempic — bioequivalence, safety, the salt form question, and a framework for evaluating your source.
Vitamin D was supposed to prevent cancer, heart disease, diabetes, and fractures. Then the randomized trials reported. What they actually found, why the 30 ng/mL target was never validated, and who still genuinely needs testing.
What's on a thyroid panel, and can a 'normal TSH' miss a thyroid problem? TSH, free T4, free T3, and TPO antibodies explained — when one number is enough, when it isn't, and where 'optimal TSH' marketing overreaches.
What do ALT, AST, and GGT really tell you? The liver enzymes on your blood panel — why a 'normal' ALT can miss fatty liver, what GGT reveals about metabolic and heart risk, and when an elevation matters.
Standard cholesterol panels miss the biomarkers that actually predict cardiovascular risk. ApoB, Lp(a), and why a normal LDL-C does not mean your cardiovascular risk is under control.
Lipoprotein(a) — or Lp(a) — is a genetically inherited cardiovascular risk factor that affects 1 in 5 people and is almost never ordered by primary care. What it is, how to test it, and what to do about it.
High-sensitivity CRP is one of the most underused metabolic risk markers in primary care. What hsCRP measures, how it connects insulin resistance to cardiovascular disease, and what actually moves the number.
LDL cholesterol is the most commonly cited cardiovascular risk marker — and one of the least accurate. Why ApoB is a superior measure of atherogenic risk, how discordance works, and what your target should be.
Fatty liver disease (MASLD, formerly NAFLD) affects roughly 1 in 4 adults and is mostly undiagnosed. The new name, why it's really a metabolic disease, how it's detected, and the two new FDA-approved drugs.
Over-the-counter glucose monitors like Stelo and Lingo are marketed to healthy people for metabolic 'optimization.' What the evidence actually shows — and who really benefits.
Berberine is trending as "nature's Ozempic." What the human evidence actually shows on blood sugar, cholesterol, and weight — and why it's no substitute for GLP‑1 drugs.
Insulin resistance can develop for a decade before standard labs catch it. How to detect it early with HOMA-IR, what the numbers mean, how to order the test yourself, and how to reverse it.
What's the difference between a 'normal' and an 'optimal' lab result? How reference ranges are actually built, why 'within normal limits' can be misleading, and where 'optimal range' marketing oversells.
What blood work should you actually get every year? The complete annual panel — the foundational tests, the high-value markers most physicals skip, and the trendy tests that aren't worth your money.
Most people start Ozempic or Mounjaro without the baseline labs that flag contraindications and track progress. Exactly what to test before and during GLP‑1 therapy — and what tells you it's actually working.
The best direct-to-consumer lab testing companies compared — Function Health, Ulta Lab Tests, Inside Tracker, Everlywell, and more — on biomarker coverage, accuracy, cost, and clinical usefulness.
A single testosterone number tells you almost nothing on its own. Total vs. free testosterone, why the reference range is contested, what the large trials actually found, and when testosterone replacement is genuinely justified.
In 2002 the Women's Health Initiative frightened a generation off hormone therapy. In November 2025 the FDA began stripping the warnings back off. What the trial actually found, what the timing hypothesis does and doesn't prove, and how to think about risk in 2026.
Two large trials tested nearly identical omega-3 doses and reached opposite conclusions. Why they disagree, what the mineral oil placebo controversy means, and whether the fish oil in your cabinet does anything.
Metformin is one of the most talked-about longevity drugs — but does it actually slow aging in healthy people? An evidence-based look at the observational data, the landmark trial that stalled before it started, and the exercise trade-off.
Rapamycin (sirolimus) is the most debated drug in longevity medicine. The actual evidence — from landmark mouse lifespan studies to the randomized human trial data — and the real risks of taking it off-label for aging.
Longevity 'stacks' now run to dozens of pills a day. An audit of the supplement cabinet — what the large trials actually show, what's redundant, what carries real risk, and how to build a shorter, smarter list.
Creatine is the most studied sports supplement on earth — but the newest research is about the brain. The human evidence on creatine for cognition, memory, and menopause, and what dose actually has data behind it.
Nattokinase, an enzyme from fermented soy (natto), is marketed as a natural clot-buster for heart health. Separating the real fibrinolytic science from the supplement hype — and the bleeding risks.
Tadalafil (Cialis) is gaining serious attention as a longevity molecule. The peer-reviewed cardiovascular, mortality, and dementia evidence — and the catches that keep it from being a proven longevity drug.
BPC-157 is one of the most talked-about peptides in recovery and performance circles. The animal data is genuinely impressive. The human data is almost nonexistent. Here's what that actually means for you.
NMN and NR supplements are everywhere in longevity circles. The actual human clinical trial data on NAD+ precursors — what they do, what the evidence shows, and whether they're worth taking.
Peptides like BPC-157, CJC-1295, sermorelin, and TB-500 are everywhere in longevity circles. Cutting through the noise with honest evidence grades, regulatory context, and a framework for thinking about peptide therapy in 2026.
No articles match your search. Try a different keyword or category.